+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Thalassemia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • ID: 4852020
  • Report
  • May 2018
  • Region: Global
  • 193 pages
  • Transparency Market Research
1 of 2

Thalassemia Treatment Market - Overview

This report analyzes the current and future scenario of the global thalassemia treatment market. Large number of health care investors such as governments, social security funds, and insurance companies are struggling to meet the rising costs of medical treatments and research & development. Promising pipeline drugs and novel therapies, programs for increasing awareness about thalassemia, and rise in prevalence of thalassemia are the major drivers of the global thalassemia treatment market.

The global thalassemia treatment market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on treatment type and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises pipeline of thalassemia treatment by country/region, prevalent treatment regimens by country/region, and cost of treatment by region/country to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global thalassemia treatment market.

Based on treatment type, the global thalassemia treatment market has been segmented into blood transfusion, chelating therapy, bone marrow transplant, others (surgery, general medicines, etc.). These segments have been analyzed based on available approved treatment procedure, cost-effectiveness, and preference for treatment by physicians and patients. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Geographically, the global thalassemia treatment market has been categorized into five major regions and the key countries in the respective region: North America (the U.S. and Canada), Europe (the U.K., Germany, Russia, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, ASEAN countries, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

The report also profiles major players in the global thalassemia treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include bluebird bio, Inc., Acceleron Pharma, Inc., Novartis AG, Celgene Corporation, Shire plc (Takeda Pharmaceuticals), Incyte Corporation, Kiadis Pharma, Gamida Cell, Bellicum Pharmaceuticals, and GlaxoSmithKline plc.

Note: Product cover images may vary from those shown
2 of 2
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Thalassemia Treatment Market

Chapter 4. Market Overview
4.1. Introduction
4.1.1. Treatment Type Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity
4.4. Global Thalassemia Treatment Market Analysis and Forecasts, 2016-2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
4.6. Market Outlook
4.7. Pipeline of Thalassemia Treatment
4.8. Prevalence & Demography - Thalassemia Disease - by Region/Country
4.8.1. North America
4.8.2. Europe
4.8.3. Asia Pacific
4.8.4. Latin America
4.8.5. Middle East & Africa
4.9. Cost of Treatment-By Region/Country
4.9.1. North America
4.9.2. Europe
4.9.3. Asia Pacific
4.9.4. Latin America
4.9.5. Middle East & Africa
4.10. Prevalent Treatment Regimens - By Country/Region
4.10.1. Asia Pacific
4.10.2. Middle East & Africa
4.11. List of Major Hospitals for Thalassemia Treatment - By Region/ Country/State
4.11.1. North America
4.11.2. Europe
4.11.3. Asia Pacific
4.11.4. Latin America
4.11.5. Middle East & Africa
4.12. Regulatory Scenario, by Region
4.12.1. North America
4.12.2. Europe
4.12.3. Asia Pacific

Chapter 5. Global Thalassemia Treatment Market Analysis and Forecasts, by Treatment Type
5.1. Introduction & Definition
5.2. Key Findings/Developments
5.3. Market Value Forecast, by Treatment Type, 2016-2026
5.3.1. Blood Transfusion
5.3.2. Chelation Therapy
5.3.3. Bone Marrow Transplant
5.3.4. Others
5.4. Market Attractiveness, by Treatment Type

Chapter 6. Global Thalassemia Treatment Market Analysis and Forecasts, by Region
6.1. Key Findings
6.2. Market Value Forecast, by Region
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East & Africa
6.3. Market Attractiveness, by Country/Region

Chapter 7. North America Thalassemia Treatment Market Analysis and Forecast
7.1. Introduction
7.1.1. Key Findings
7.2. Market Value Forecast, by Treatment Type, 2016-2026
7.2.1. Blood Transfusion
7.2.2. Chelation Therapy
7.2.3. Bone Marrow Transplant
7.2.4. Others
7.3. Market Value Forecast, by Country, 2016-2026
7.3.1. U.S.
7.3.2. Canada
7.4. Market Attractiveness Analysis
7.4.1. By Treatment Type
7.4.2. By Country

Chapter 8. Europe Thalassemia Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.2. Market Value Forecast, by Treatment Type, 2016-2026
8.2.1. Blood Transfusion
8.2.2. Chelation Therapy
8.2.3. Bone Marrow Transplant
8.2.4. Others
8.3. Market Value Forecast, by Country/Sub-region, 2016-2026
8.3.1. Germany
8.3.2. U.K.
8.3.3. France
8.3.4. Spain
8.3.5. Italy
8.3.6. Rest of Europe
8.4. Market Attractiveness Analysis
8.4.1. By Treatment Type
8.4.2. By Country/Sub-region

Chapter 9. Asia Pacific Thalassemia Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Treatment Type, 2016-2026
9.2.1. Blood Transfusion
9.2.2. Chelation Therapy
9.2.3. Bone Marrow Transplant
9.2.4. Others
9.3. Market Value Forecast, by Country/Sub-region, 2016-2026
9.3.1. China
9.3.2. India
9.3.3. ASEAN countries
9.3.4. Rest of Asia Pacific
9.4. Market Attractiveness Analysis
9.4.1. By Treatment Type
9.4.2. By Country/Sub-region

Chapter 10. Latin America Thalassemia Treatment Market Analysis and Forecast
10.1.Introduction
10.1.1. Key Findings
10.2.Market Value Forecast, by Treatment Type, 2016-2026
10.2.1. Blood Transfusion
10.2.2. Chelation Therapy
10.2.3. Bone Marrow Transplant
10.2.4. Others
10.3.Market Value Forecast, by Country/Sub-region, 2016-2026
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4.Market Attractiveness Analysis
10.4.1. By Treatment Type
10.4.2. By Country/Sub-region

Chapter 11. Middle East & Africa Thalassemia Treatment Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2.Market Value Forecast, by Treatment Type, 2016-2026
11.2.1. Blood Transfusion
11.2.2. Chelation Therapy
11.2.3. Bone Marrow Transplant
11.2.4. Others
11.3.Market Value Forecast, by Country/Sub-region, 2016-2026
11.3.1. GCC countries
11.3.2. South Africa
11.3.3. Rest of Middle East & Africa
11.4.Market Attractiveness Analysis
11.4.1. By Treatment Type
11.4.2. By Country/Sub-region

Chapter 12. Competition Landscape
12.1.Market Player - Market Presence (2017)
12.1.1. Current Offerings
12.1.2. Strategy
12.2.Company Profiles
12.2.1. bluebird bio, Inc.
12.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.1.2. Product Portfolio
12.2.1.3. SWOT Analysis
12.2.1.4. Financial Overview
12.2.1.5. Strategic Overview
12.2.2. Acceleron Pharma, Inc.
12.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.2.2. Product Portfolio
12.2.2.3. SWOT Analysis
12.2.2.4. Financial Overview
12.2.2.5. Strategic Overview
12.2.3. Novartis AG
12.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.3.2. Product Portfolio
12.2.3.3. SWOT Analysis
12.2.3.4. Financial Overview
12.2.3.5. Strategic Overview
12.2.4. Celgene Corporation
12.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.4.2. Product Portfolio
12.2.4.3. SWOT Analysis
12.2.4.4. Financial Overview
12.2.4.5. Strategic Overview
12.2.5. Shire Plc. (Takeda Pharmaceuticals)
12.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.5.2. Product Portfolio
12.2.5.3. SWOT Analysis
12.2.5.4. Financial Overview
12.2.5.5. Strategic Overview
12.2.6. Incyte Corporation
12.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.6.2. Product Portfolio
12.2.6.3. SWOT Analysis
12.2.6.4. Financial Overview
12.2.6.5. Strategic Overview
12.2.7. Kiadis Pharma
12.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.7.2. Product Portfolio
12.2.7.3. SWOT Analysis
12.2.7.4. Financial Overview
12.2.7.5. Strategic Overview
12.2.8. Bellicum Pharmaceuticals
12.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.8.2. Product Portfolio
12.2.8.3. SWOT Analysis
12.2.8.4. Financial Overview
12.2.8.5. Strategic Overview
12.2.9. GlaxoSmithKline plc
12.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.9.2. Product Portfolio
12.2.9.3. SWOT Analysis
12.2.9.4. Financial Overview
12.2.9.5. Strategic Overview
12.2.10. Others
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll